CaaMTech is an Issaquah, Washington drug discovery company building patentable, psychedelic-inspired medicines. Founded in 2016 by chemist and patent attorney Andrew Chadeayne, it has synthesized and characterized a large library of novel tryptamines, solved crystal structures of compounds like 4-AcO-DMT and norpsilocin, and filed more than 100 patent applications. The company studies the 'entourage effect' in magic mushrooms to engineer compounds that keep the benefits while reducing side effects, and in 2021 raised a $22M Series A to push lead candidates toward human trials.
Andrew Chadeayne is the founder and CEO of CaaMTech, an Issaquah, Washington psychedelic pharmaceutical company building safer, patentable psychedelic-inspired medicines. A chemist (PhD, Cornell) and patent attorney (JD, George Washington) who began his career proving sugar is addictive through opioid pathways, he has filed more than 100 patent applications mapping the chemistry of psilocybin, tryptamines and other psychedelics. His strategy is to expand 'the universe of available compounds' rather than bet on a single molecule, giving researchers a toolbox of characterized psychedelics for mental health treatment.